A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Single and Multiple Ascending Doses of Kylo-0603 Capsules in Healthy Subjects
Latest Information Update: 14 Oct 2024
At a glance
- Drugs Kylo 0603 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; First in man
- Sponsors Kylonova (Xiamen) Biopharma
Most Recent Events
- 09 Oct 2024 Status changed from recruiting to completed.
- 18 Apr 2024 New trial record